Related Experiment Video

Updated: Apr 17, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.5K

CXCL9 and CXCL10 gene polymorphisms in patients with rheumatoid arthritis

Daniel Kotrych1, Violetta Dziedziejko, Krzysztof Safranow

  • 1Departament of Orthopaedics, Traumatology and Orthopaedic Oncology, Pomeranian Medical University, Szczecin, Poland.

Rheumatology International
|February 23, 2015
PubMed

Insights

Genetic variations in the CXCL10 gene are linked to rheumatoid arthritis (RA) and its extra-articular manifestations. No significant association was found for CXCL9 gene polymorphisms in RA patients.

Area of Science:

  • Immunogenetics
  • Rheumatology

Background:

  • Chemokines (CXCL) and their receptors are implicated in the pathogenesis of rheumatoid arthritis (RA).
  • Understanding the genetic basis of RA susceptibility and clinical manifestations is crucial for targeted therapies.

Purpose of the Study:

  • To investigate the association between specific polymorphisms in the CXCL9 (rs3733236 G>A) and CXCL10 (rs8878 A>G) genes and the risk of developing RA.
  • To explore the relationship between these gene polymorphisms and clinical features of RA, including extra-articular manifestations.

Main Methods:

  • Genotyping of single nucleotide polymorphisms (SNPs) in CXCL9 and CXCL10 genes using TaqMan assays.
  • Case-control study involving 422 RA patients and 338 healthy controls.
  • Statistical analysis including genotype and allele frequency distributions, odds ratios, and multivariate regression.

Main Results:

  • No significant association was observed between CXCL9 (rs3733236) genotypes/alleles and RA.
  • A significant association was found between the CXCL10 (rs8878) G allele and an increased risk of RA (AG+GG vs AA).
  • The CXCL10 GG genotype was significantly associated with an increased frequency of extra-articular manifestations in RA patients.
  • Multivariate analysis confirmed the CXCL10 GG genotype as an independent factor for increased risk of extra-articular manifestations.

Conclusions:

  • The CXCL10 gene polymorphism (rs8878 A>G) is associated with rheumatoid arthritis and its extra-articular manifestations.
  • CXCL9 gene polymorphism (rs3733236 G>A) does not appear to be associated with RA risk or clinical features in this cohort.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
95
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.5K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
20.3K